Genomic Biomarker Market Report 2026

Genomic Biomarker Market Overview

• Genomic Biomarker market size has reached to $9.9 billion in 2025 • Expected to grow to $22.23 billion in 2030 at a compound annual growth rate (CAGR) of 17.5% • Growth Driver: Impact of Chronic Disease Prevalence on Genomic Biomarker Market Growth • Market Trend: Technological Advances In Genomic biomarkers-global-market-report" target="_blank">biomarkers • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Genomic Biomarker Market?

A genomic biomarker is a specific genetic sequence or molecular characteristic found in an individual's genome that can assess disease risk, predict disease progression, or determine response to a particular treatment. These biomarkers are often used in personalized medicine to tailor treatments based on an individual's genetic profile. The main types of genomic biomarkers are predictive biomarkers and prognostic biomarkers. Predictive biomarkers are biological markers used to identify how likely a patient is to respond to a specific treatment or drug. It is used for various diseases such as oncology, cardiovascular diseases, neurological diseases, renal disorders, and others, and it provides analytical validation, clinical validation, and clinical utility. It is used by various end users, including hospitals, diagnostic centers, research laboratories, and others.

What Is The Genomic Biomarker Market Growth Forecast?

The genomic biomarker market size is expected to see rapid growth in the next few years. It will grow to $22.23 billion in 2030 at a compound annual growth rate (CAGR) of 17.5%. The growth in the forecast period can be attributed to increasing demand for precision medicine therapies, rising use of biomarkers in drug development, expansion of companion diagnostics adoption, growing focus on early disease detection, increasing regulatory support for biomarker-based approvals. Major trends in the forecast period include increasing adoption of predictive genomic biomarkers, rising use of pharmacogenomic testing, growing integration of genomic data in clinical decision-making, expansion of biomarker-based oncology diagnostics, enhanced focus on clinical validation standards.

Global Genomic Biomarker Market Segmentation

1) By Type: Predictive Biomarkers, Prognostic Biomarkers 2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications 3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility 4) By End-User: Hospitals, Diagnostic Centers, Research Laboratories, Other End Users Subsegments: 1) By Predictive Biomarkers: Genetic Biomarkers For Disease Susceptibility, Pharmacogenomic Biomarkers For Drug Response, Early Detection Biomarkers For Disease Prediction, Biomarkers For Treatment Response Prediction 2) By Prognostic Biomarkers: Biomarkers For Disease Progression, Biomarkers For Outcome Prediction, Survival And Recurrence Biomarkers, Biomarkers For Treatment Efficacy And Prognosis

What Is The Driver Of The Genomic Biomarker Market?

The increasing prevalence of chronic diseases is expected to propel the growth of the genomic biomarker market going forward. Chronic diseases are long-lasting health conditions that persist over time and often progress slowly. The increasing prevalence of chronic diseases is due to aging populations and rising rates of lifestyle-related conditions such as obesity and diabetes. Genomic biomarkers enable early detection and personalized prevention strategies for chronic diseases by identifying genetic predispositions and tailoring interventions. This proactive approach helps reduce prevalence by targeting at-risk individuals before disease onset. For instance, in September 2023, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, each year, there are 41 million deaths worldwide, accounting for 74% of all fatalities attributed to chronic diseases. This includes 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Therefore, the increasing prevalence of chronic diseases drives the growth of genomic biomarkers.

Key Players In The Global Genomic Biomarker Market

Major companies operating in the genomic biomarker market are Pfizer Inc., Roche Diagnostics, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Foundation Medicine Inc., QIAGEN N.V., Almac Group Ltd., Myriad Genetics Inc., Invitae Inc., Guardant Health Inc., Novogene Inc., Twist Bioscience Corp., NanoString Technologies Inc., Quanterix Corp., Personalis Inc., GENEWIZ Inc., Agena Bioscience Inc., Creative Diagnostics Ltd., OncoDNA SA, Genome Life Sciences Ltd., Epigenomics AG.

Global Genomic Biomarker Market Trends and Insights

Major companies operating in the genomic biomarker market are focusing on developing advanced products, such as advanced liquid biopsy assays, to enable comprehensive genomic profiling of solid tumors. A liquid biopsy assay is a diagnostic test that analyzes genetic material, typically circulating tumor DNA (ctDNA), from a blood sample to detect and monitor cancer. Identifying genomic biomarkers can provide information about specific mutations, gene expression profiles, or other genetic alterations associated with cancer. For instance, in November 2023, Illumina Inc., a US-based biotechnology company, launched an advanced liquid biopsy assay, the TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), for comprehensive genomic profiling of solid tumors. The assay offers enhanced analytical sensitivity by detecting low-frequency variants with just 20 ng of cell-free DNA, down from 30 ng. It delivers results in under four days, greatly accelerating genomic profiling compared to traditional methods. The streamlined workflow and forthcoming automation will simplify lab integration and boost efficiency.

What Are Latest Mergers And Acquisitions In The Genomic Biomarker Market?

In February 2024, Veracyte, a US-based diagnostics company, acquired C2i Genomics for up to US$ 95 million. Through this acquisition, Veracyte aims to strengthen its cancer diagnostics portfolio by integrating C2i Genomics’ whole-genome, AI-powered minimal residual disease (MRD) detection assays and expanding its capabilities in genomic biomarker-based cancer monitoring. C2i Genomics is a US-based biotechnology company that provides genomic assays for detecting minimal residual disease in blood using whole-genome sequencing and AI algorithms.

Regional Insights

North America was the largest region in the genomic biomarker market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Genomic Biomarker Market?

The genomic biomarker market consists of sales of genetic testing kits, genotyping arrays, pharmacogenomic panels and cancer genomics panels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Genomic Biomarker Market Report 2026?

The genomic biomarker market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the genomic biomarker industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.